Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide with or without resistance exercise for obesity in older adults at cardiovascular risk
ACTRN12623001236684Phase 3Recruiting
- Sponsor
- The University of Western Australia
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in obesity and Overweight (2 arms), sponsored by The University of Western Australia. Primary endpoints: Change in lean mass at week 56 and Change in fat mass at week 56. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ACTRN12623001236684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001236684.